Musashi-2
Control Slides

CE IVD



Intended Use
For In Vitro Diagnostic Use.

Summary and Explanation
Musashi-2 is an RNA-binding protein present in the cytoplasm of hematopoietic, neuronal progenitor, and stem cells. Musashi proteins have an RNA-recognition motif used to bind and stabilize mRNA in stem cell populations. MSI2 is also present in blood cells, astrocytes, and the development of reproductive cells in spermatogenesis and oogenesis. Musashi 2 can indicate the presence of stem cells in tumors of Colorectal, Lung, and Pancreatic Cancers, and in Glioblastoma, Leukemias, and xenografts, where it supports proliferation and prevents apoptosis. It's RNA-binding ability is increased in Leukemia cells over normal hematopoietic stem cells, and it's expression in Acute Myeloid Leukemia is associated with poor prognosis. MSI2 also has a role in promoting epithelial-to-mesenchymal transition, such as in Hepatocellular Carcinoma. MSI2-HOXA9 and other fusions/ transformations are rare but MSI2 over-expression is found in almost all hematological disorders, and can be up-regulated further resulting in worse prognosis. Studies comparing normal cervical tissues have found that the expression of MSI2 is increased in cervical cancer tissues and may act as a prognostic biomarker in patients with cervical cancer. MSI2 has been found to be significantly upregulated in bladder cancer cells and tissues compared with normal bladder urothelial cells and tissues. IHC analysis has revealed high expression of MSI2 in bladder cancer specimens. It has been demonstrated that MSI2 can induce bladder cancer cell migration and invasion by activating the JAK2/STAT3 pathway, and may be a valuable prognostic biomarker for bladder cancer patients.

Presentation
Five slides of Musashi 2 positive tissues, each mounted on Hydrophilic Plus Slides, provided in a plastic mailer.

Catalog No.	*Quantity*
BSB-9293-CS	5 slides
BSB-3740-CS	5 slides

Storage Store at 20-25°C

Precautions
1. For professional users only. Results should be interpreted by a qualified medical professional.
2. Ensure proper handling procedures are used with this reagent.
3. Always wear personal protective equipment such as a laboratory coat, goggles, and gloves when handling reagents.
4. Dispose of unused solution with copious amounts of water.
5. Follow safety precautions of the heating device used for epitope retrieval (TintoRetriever Pressure Cooker or similar).
8. For additional safety information, refer to Safety Data Sheet for this product.
9. For complete recommendations for handling biological specimens, please refer to the CDC document, "Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories" (see References in this document).

Stability
This product is stable up to the expiration date on the product label.
Do not use after expiration date listed on the package label.

IHC Protocol
1. Subject tissues to heat induced epitope retrieval (HIER) using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate (BSB 0020-BSB 0023) or EDTA (BSB 0030-BSB 0033).
2. Any of three heating methods may be used:
a. TintoRetriever Pressure Cooker or Equivalent
Place tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA and place on trivet in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room temperature.
b. TintoRetriever PT Module or Water Bath Method
Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes.
c. Conventional Steamer Method
Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a steamer, cover and steam for 30-60 minutes.
3. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes.
4. For manual staining, perform antibody incubation at ambient temperature. For automated staining methods, perform antibody incubation according to instrument manufacturer's instructions.
5. Wash slides with ImmunoDNA washer or DI water.
6. Continue IHC staining protocol. Wash slides between each step with ImmunoDNA washer solution.

Abbreviated Immunohistochemical Protocol

Step	ImmunoDetector AP/HRP	PolyDetector AP/HRP	PolyDetector Plus HRP
Peroxidase/AP Blocker	5 min.	5 min.	5 min
Primary Antibody	30-60 min.	30-60 min.	30-60 min.
1st Step Detection	10 min.	30-45 min.	15 min.
2nd Step Detection	10 min.	Not Applicable	15 min.
Substrate- Chromogen	5-10 min.	5-10 min.	5-10 min.
Counterstain / Coverslip	Varies	Varies	Varies

Abbreviated IF Protocol

Step	Incubation Time
Rinse slides in IF wash buffer	5 minutes
Drain and wipe excess IF wash buffer off slide	
Conduct remaining steps in the dark	
Apply Antibody	30-60 minutes
Rinse with 3 changes of IF wash buffer	3x15 minutes each
Coverslip with IF mounting medium	

Mounting Protocols

For detailed instructions using biodegradable permanent mounting media such as XyGreen PermaMounter (BSB 0169-0174) or organic solvent based resin such as PermaMounter (BSB 0094-0097), refer to PI0174 or PI0097.

Product Limitations

Due to inherent variability present in immunohistochemical procedures (including fixation time of tissues, dilution factor of antibody, retrieval method utilized, and incubation time), optimal performance should be established through the use of positive and negative controls. Results should be interpreted by a qualified medical professional.

References

1. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16(8):903-908. doi:10.1038/nm.2187
2. Kharas MG, Lengner CJ. Stem Cells, Cancer, and MUSASHI in Blood and Guts. Trends Cancer. 2017;3(5):347-356. doi:10.1016/j.trecan.2017.03.007
3. Kudinov AE, Karanicolas J, Golemis EA, Boumber Y. Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. Clin Cancer Res. 2017;23(9):2143-2153. doi:10.1158/1078-0432.CCR-16-2728
4. Nguyen DTT, Lu Y, Chu KL, et al. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nat Commun. 2020;11(1):2026. Published 2020 Apr 24. doi:10.1038/s41467-020-15814-8
5. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118(10):2857-2867. doi:10.1182/blood-2011-04-346767
6. Liu Y, Fan Y, Wang X, Huang Z, Shi K, Zhou B. Musashi-2 is a prognostic marker for the survival of patients with cervical cancer. Oncol Lett. 2018;15(4):5425-5432. doi:10.3892/ol.2018.8077
7. Yang C, Zhang W, Wang L, et al. Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway. Lab Invest. 2016;96(9):950-958. doi:10.1038/labinvest.2016.71
8. U.S. Department of Health and Human Services: Centers for Disease Control and Prevention. Guidelines for Safe WorkPractices in Human and Animal Medical Diagnostic Laboratories. Supplement / Vol. 61, January 6, 2012. https://www.cdc.gov/mmwr/pdf/other/su6101.pdf

Symbol Key / Légende des symboles/Erläuterung der Symbole

EC REP QAdvis EAR AB Ideon Science Park Scheelevägen 17 SE-223 70 Lund, Sweden	Storage Temperature Limites de température Zulässiger Temperaturbereich	Manufacturer Fabricant Hersteller	REF Catalog Number Référence du catalogue Bestellnummer
IVD In Vitro Diagnostic Medical Device Dispositif médical de diagnostic in vitro In-Vitro-Diagnostikum	Read Instructions for Use Consulter les instructions d'utilisation Gebrauchsanweisung beachten	Expiration Date Utiliser jusque Verwendbar bis	LOT Lot Number Code du lot Chargenbezeichnung

Bio SB
BIOSCIENCE FOR THE WORLD
5385 Hollister Avenue, Bldg. 8, Ste. 108, Santa Barbara, CA 93111, USA
Tel. (805) 692-2768 | Tel. (800) 561-1145 | Fax. (805) 692-2769
E-mail: sales@biosb.com | Website: www.biosb.com